January 31, 2011, Rutherford, N.J. –– Ceva Animal Health, LLC, addresses questions pertaining to Ceva’s relationship with third parties having interests in the “over-the-counter” parasiticide market, and the potential impact on Ceva’s continued commitment to exclusively marketing its Vectra line of products through ethical channels.  Ceva reassures veterinarians of its unwavering dedication to maintaining exclusivity with its Vectra line of products through veterinarians and veterinary hospitals, as evidenced by the development and implementation of proprietary Bloodhound Track and Trace technology.

“We empathically deny competitor claims that interests of Ceva’s equity partner, Sumitomo Corporation of America, may represent a conflict of interest with marketing the Vectra line of products exclusively through ethical channels.  Such claims are unsubstantiated and the parties making these suggestions fail to understand Ceva is a majority-owned subsidiary of Ceva Sante Animale, the eighth largest animal health company in the world,” said Brad Butler, Chief of Operations, Ceva Animal Health, LLC.  He continued, “We firmly believe the professional advice provided by veterinarians is essential when dispensing and using parasiticide products on cats and dogs.”

Ceva is fully dedicated to marketing its Vectra products exclusively through ethical channels and is under no obligation to any third party that would conflict with this commitment.  Specifically, Ceva wishes to emphasize that Sergeant’s recent announcement concerning an agreement with Sumitomo Chemical Company has no direct impact on Ceva.  Ceva’s minority equity partner, Sumitomo Corporation of America, and its parent company Sumitomo Corporation, are completely different entities from Sumitomo Chemical Company; they operate totally independent and autonomous of each other.

About Ceva Animal Health : Ceva’s key companion animal products include the Vectra® line of parasiticides, D.A.P.® and Feliway® pheromone behavior aids and Senilife® neuroprotection for aging pets.  Ceva Biomune’s key poultry products include CEVAC® Transmune IBD, Vectormune® FP and Vectormune® HVT.  Ceva Biomune Campus and the North America Zone headquarters are both located in Lenexa, Kansas.  Visit www.ceva.us.

About Ceva Santé Animale: Ceva’s parent company is a global veterinary health company focused on the research, development, production and marketing of pharmaceutical products and vaccines for pets, livestock, swine and poultry.  Its headquarters is in Libourne, France. Visit www.ceva.com.

For more information, please contact Carolyn Gilliland at carolyn.gilliland[at]ceva.com or 913.945.4448.

###